ReviewHeart international2022
COVID-19 and Myocarditis: Review of Clinical Presentations, Pathogenesis and Management.
Review in Heart international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Multisystem inflammatory syndrome in adults (MIS-A): cardiovascular manifestations and in-hospital outcomes from two tertiary centers.Frontiers in cardiovascular medicine · 2026Article
- COVID-19-Associated Myocarditis Managed With High-Dose Steroids: A Case of Rapid Clinical and Biochemical Recovery.Cureus · 2025Article
- COVID-19 and Myocarditis: Trends, Clinical Characteristics, and Future Directions.Journal of clinical medicine · 2025Review
- Myocardial Fibrosis in a Recovered COVID-19 Patient: A Case Indicating Prior Myocarditis.Cureus · 2025Article
- Review
- Identification of Potential Biomarkers and Immune Cell Signatures in COVID-19 Myocarditis Through Bioinformatic Analysis.Cardiology research and practice · 2025Article
- Subtle changes on electrocardiogram in severe patients with COVID-19 may be predictors of treatment outcome.Frontiers in artificial intelligence · 2025Article
- Clinical Presentation and Outcomes of Myocarditis Among the COVID-19 Pediatric Population: A Review of 100 Cases.Cureus · 2024Article
- Quantification of hs-Troponin Levels and Global Longitudinal Strain among Critical COVID-19 Patients with Myocardial Involvement.Journal of clinical medicine · 2024Article
- SARS-CoV-2 spread to endocrine organs is associated with obesity: an autopsy study of COVID-19 cases.Endocrine · 2024Article
- Sex differences in coronavirus disease 2019 myocarditis.Current opinion in physiology · 2023Article
- Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature.Cureus · 2023Review
- ERS International Congress 2022: highlights from the Respiratory Clinical Care and Physiology Assembly.ERJ open research · 2023Article
- COVID-19, Myocarditis and Pericarditis.Circulation research · 2023Review
- Article
- Complete recovery after fulminant myocarditis in a patient with COVID-19.Pakistan journal of medical sciencesArticle
- Do COVID-19 viral infection and its mRNA vaccine carry an equivalent risk of myocarditis? Review of the current evidence, insights, and future directions.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
There are four main myocarditis presentations identified in the context of severe acute respiratory coronavirus 2 (SARS-CoV-2): myocarditis associated with acute coronavirus disease 2019 (COVID-19) infection, post-acute COVID-19 syndrome, multisystem inflammatory syndrome, and vaccination-associated myocarditis. This article reviews the clinical features and current management strategies for each of these presentations. The overall prevalence of myocarditis is considered to be rare, although accurate estimation is affected by heterogeneity in diagnostic criteria and reporting, as well as infrequent use of gold-standard diagnostic endomyocardial biopsy. Severity of disease can range from mild symptoms to fulminant myocarditis. Therapeutic interventions are typically supportive and extrapolated from treatment for non-COVID-19 viral myocarditis. Several pathogenic mechanisms for the development of myocarditis have been proposed, and ongoing research is critical for elucidating disease pathogenesis and potentially identifying therapeutic targets. The long-term cardiovascular sequelae of SARS-CoV-2 infections and associated myocarditis require further elucidation and understanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.